
FDA Backs Darovasertib Phase 3 Trial Design in Uveal Melanoma
A successful Type D meeting between the FDA and IDEAYA Biosciences discussed the design of a phase 3 registrational trial evaluating darovasertib for primary uveal melanoma. Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being …